Previous 10 | Next 10 |
adrian825/iStock via Getty Images Psychedelic drug developers started as buys Citi, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald have initiated Atai Life Sciences ([[ATAI]] +2.3%) with buy/overweight ratings. Credit Suisse has a $25 price target on shares (~35% upside) Credit...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 17, 2021 – What was once a war on drugs has turned into a public push for the decriminalization and legalization of illegal drugs with potential therapeutic benefits. Leg...
Yarygin/iStock via Getty Images Recently, a bill to decriminalize psychedelic substances has passed the California state Senate on a 21-16 vote. Senate Bill 519 would allow those aged 21 years and older to possess psilocybin (magic mushrooms) for personal use and “social sharing.&...
naphtalina/iStock via Getty Images Talkspace initiated as outperform at Baird Baird has initiated online therapy provider Talkspace ([[TALK]] -8.4%) with an outperform rating and a $10 price target (~50% upside). Analyst Vikram Kesavabhotla says he expects to company to benefit from broader t...
Palm Beach, FL – July 7, 2021 – Psychedelic drugs and therapies are truly becoming mainstream and are expected to become even more so in the years to come. Psychedelic drugs involve various types of chemical substances including LSD and chemical extracted from plants. Psychede...
Mental health is on the decline all over the world. At the moment, nearly 264 million people are struggling with depression, for example. To help alleviate the symptoms of depression, many turn to anti-depressants such as SSRIs (selective serotonin reuptake inhibitors). Problem is -- SSRIs ...
London, UK, July 07, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Lars Wilde, President, Chief Business Officer, and Co‑founder, ...
London, UK – 5 July 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has signed a Memorandum of Understanding (MoU) with South London and Maudsl...
London, UK – 30 June 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, launched a new podcast today – “Everyone has a sto...
NetworkNewsWire Editorial Coverage : In May 2013, GW Pharma listed on Nasdaq, selling 3.5 million shares at $8.90 each to investors betting that GW was charting a profitable course as a biotech developing new drugs from cannabis-derived compounds. Legal cannabis was only beginning to gain...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...